Clinical Trials on Influenza, Human in Germany

Total 499 results

Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above

Human Influenza

Germany
GlaxoSmithKline

Completed

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

Belgium, Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects

Seasonal Influenza

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above

Influenza | Human

Germany
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Seasonal Influenza | Vaccine

Germany
Abbott Biologicals

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season

Prophylaxis of Influenza

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza, Vaccine

Germany
University Medicine Greifswald

Active, not recruiting

Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI) ((AIGI))

Seasonal Influenza Vaccination

Germany
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010

Seasonal Influenza

Germany
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Adults

Influenza | Pandemic Influenza

Austria, Germany
Sanofi

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Influenza Immunization (Healthy Volunteers)

Finland, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
ModernaTX, Inc.

Completed

Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects

Influenza

Germany
Charite University, Berlin, Germany
Hoffmann-La Roche

Completed

Oseltamivir Infant Influenza Safety Study

Influenza, Human

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects

Influenza

Germany
GlaxoSmithKline

Completed

Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03

Influenza

Germany
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

Influenza

Germany
Robert Koch Institut

Completed

Tolerability and Measurability of the Efficacy of Non Pharmaceutical Measures to Prevent Seasonal Influenza

Influenza

Germany
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Germany
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects

Influenza

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older

Influenza

Germany
GlaxoSmithKline

Completed

A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above

Influenza

Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Dominican Republic, Belgium, Germany
Solvay Pharmaceuticals

Withdrawn

Annual Study to Investigate Inactivated Virosomal Influenza Vaccine for the 2006/2007 Influenza Season in Europe.

Healthy Volunteers

Germany
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Influenza | Pandemic Influenza

Austria, Germany
Novartis Vaccines

Completed

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011

Seasonal Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or Above

Influenza

Germany
Ology Bioservices

Completed

Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
Abbott Biologicals
Quintiles, Inc.

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season

Influenza

Belgium, Germany
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

Influenza

Germany
GlaxoSmithKline

Completed

A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults

Influenza

Germany
Abbott Biologicals
Quintiles, Inc.

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season

Influenza

Belgium, Germany
Solvay Biologicals

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 08/09 Season.

Influenza

Belgium, Germany
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008

Seasonal Influenza Vaccine

Germany
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes

Influenza

Germany
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
Ology Bioservices

Completed

Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005

Influenza

Austria, Germany
Solvay Pharmaceuticals

Completed

Annual Study to Investigate Influenza Vaccine Due to New Virus Strains for the 2007/2008 Influenza Season in Europe

Healthy Volunteers

Belgium, Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older

Influenza

Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Netherlands, Belgium, Chile, Dominican Republic, Germany
University of Rostock
Sanofi Pasteur, a Sanofi Company; Klinikum Ernst von Bergmann Potsdam; Klinikum...

Unknown

Burden of Influenza at Emergency Department (ED) Level in European Countries

Influenza, Human

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity Study of the Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infections

Belgium, Germany, Switzerland
GlaxoSmithKline

Completed

Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population

Influenza | Influenza Vaccines

Germany

3

Subscribe